What is Tandem Diabetes Care's commercial paper outstanding?

Tandem Diabetes Care (TNDM) reported commercial paper outstanding of $4.9M in Q1 2026.

How has Tandem Diabetes Care's commercial paper outstanding changed year-over-year?

Tandem Diabetes Care's commercial paper outstanding decreased by 0.0% year-over-year, from $4.9M to $4.9M.

Tandem Diabetes Care TNDM Commercial Paper Outstanding

Other financials

Income statement

See full

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

See full

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

See full

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation

See full

Market cap$1.08B-19.8%

Enterprise value$1.64B-8.5%

P/S1.1×-0.3×

Profitability

See full

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Returns & leverage

See full

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:LettersOfCreditOutstandingAmount.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's commercial paper outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tandem Diabetes Care's commercial paper outstanding?: Tandem Diabetes Care (TNDM) reported commercial paper outstanding of $4.9M in Q1 2026.
How has Tandem Diabetes Care's commercial paper outstanding changed year-over-year?: Tandem Diabetes Care's commercial paper outstanding decreased by 0.0% year-over-year, from $4.9M to $4.9M.